In Friday’s Wall Street session, Werewolf Therapeutics Inc (NASDAQ:HOWL) shares traded at $1.15, up 3.60% from the previous session.
HOWL stock price is now 21.81% away from the 50-day moving average and -29.03% away from the 200-day moving average. The market capitalization of the company currently stands at $51.60M.
With the price target of $12, JMP Securities recently initiated with Mkt Outperform rating for Werewolf Therapeutics Inc (NASDAQ: HOWL). On August 24, 2023, Wedbush recently initiated its ‘Outperform’ rating on the stock quoting a target price of $9, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, RA CAPITAL MANAGEMENT, L.P., Director bought 320,913 shares of the company’s stock on May 12 ’25. The stock was bought for $275,985 at an average price of $0.86. Upon completion of the transaction, the Director now directly owns 6,021,969 shares in the company, valued at $6.93 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 14 ’25, Director RA CAPITAL MANAGEMENT, L.P. bought 162,539 shares of the business’s stock. A total of $159,288 was incurred on buying the stock at an average price of $0.98. This leaves the insider owning 6,237,482 shares of the company worth $7.17 million. A total of 26.20% of the company’s stock is owned by insiders.
During the past 12 months, Werewolf Therapeutics Inc has had a low of $0.60 and a high of $5.73. As of last week, the company has a debt-to-equity ratio of 0.65, a current ratio of 8.09, and a quick ratio of 8.09. The fifty day moving average price for HOWL is $0.94412 and a two-hundred day moving average price translates $1.620505 for the stock.
The latest earnings results from Werewolf Therapeutics Inc (NASDAQ: HOWL) was released for 2025-03-31. The net profit margin was -6335.17% and return on equity was -82.81% for HOWL.
